# US 2018/0021288 A1 · Neuroprotection in Demyelinating Diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021288 A1
- Document ID: US20180021288A1
- Status: Published application
- Kind: A1
- Application number: 15/644,029
- Filed: 2017-07-07
- Published: 2018-01-25
- Earliest claimed: 2010-02-12
- Assignees: Biogen MA Inc.
- Applicants: Biogen MA Inc.
- Inventors: Susan Goelz; Katherine Dawson; Ralf Linker; Ralf Gold
- Web page: https://patentgrep.com/patent/US20180021288A1

## CPC

- A61K 31/225: Polycarboxylic acids
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/785: Polymers containing nitrogen
- A61K 38/02: Peptides of undefined number of amino acids; Derivatives thereof
- A61K 38/215: {IFN-beta}
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating neurological disorders, e.g., those characterized by demyelination and/or axonal loss (e.g., MS), are provided. The methods comprise administration of a therapeutically effective amount of at least one compound of Formula I: wherein R1 and R2 are independently selected from OH, O−, and (C1-6)alkoxy, or a pharmaceutically acceptable salt thereof; and either glatiramer acetate or interferon-beta.

## Claims

### Claim at position 1

1-50. (canceled)

### Claim 51

A method of treating a subject having multiple sclerosis (MS), the method consisting essentially of:
(a) administering to the subject a therapeutically effective amount of at least one compound of Formula I:
wherein R1 and R2 are independently selected from OH, O−, and (C1-6)alkoxy, or a pharmaceutically acceptable salt thereof, optionally in combination with one or more pharmaceutically acceptable excipients; and
(b) administering to the subject a therapeutically effective amount of glatiramer acetate, optionally in combination with one or more pharmaceutically acceptable excipients.

### Claim 52 (depends on 51)

The method of claim 51, wherein the MS is selected from relapsing remitting MS, secondary progressive MS, primary progressive MS, progressive relapsing MS, and clinically isolated syndrome.

### Claim 53 (depends on 51)

The method of claim 51, wherein the at least one compound of Formula I is chosen from dimethyl fumarate (DMF), monomethyl fumarate (MMF), and combinations thereof.

### Claim 54 (depends on 53)

The method of claim 53, wherein the at least one compound of Formula I is DMF.

### Claim 55 (depends on 54)

The method of claim 54, wherein about 240 mg of DMF is administered to the subject at one time.

### Claim 56 (depends on 55)

The method of claim 55, wherein the DMF is administered to the subject two times per day (BID) equivalent to a total daily dose of about 480 mg/day.

### Claim 57 (depends on 51)

The method of claim 51, wherein about 20 mg/day of glatiramer acetate is administered to the subject.

### Claim 58 (depends on 51)

The method of claim 51, wherein less than about 20 mg/day of glatiramer acetate is administered to the subject.

### Claim 59 (depends on 51)

The method of claim 51, wherein the compound of Formula I and the glatiramer acetate are administered in amounts and for periods of time sufficient to reduce a relapse rate in the subject.

### Claim 60 (depends on 51)

The method of claim 51, wherein the compound of Formula I and the glatiramer acetate are administered in amounts and for periods of time sufficient to reduce demyelination and/or axonal death in the subject.

### Claim 61

A method of treating a subject having multiple sclerosis (MS), the method comprising:
(a) administering to the subject a therapeutically effective amount of at least one compound of Formula I:
wherein R1 and R2 are independently selected from OH, O−, and (C1-6)alkoxy, or a pharmaceutically acceptable salt thereof; and
(b) administering to the subject a therapeutically effective amount of glatiramer acetate; wherein the compound of Formula I and the glatiramer acetate are the only active agents administered to said subject for said treating.

### Claim 62 (depends on 61)

The method of claim 61, wherein the MS is selected from relapsing remitting MS, secondary progressive MS, primary progressive MS, progressive relapsing MS, and clinically isolated syndrome.

### Claim 63 (depends on 61)

The method of claim 61, wherein the at least one compound of Formula I is chosen from dimethyl fumarate (DMF), monomethyl fumarate (MMF), and combinations thereof.

### Claim 64 (depends on 63)

The method of claim 63, wherein the at least one compound of Formula I is DMF.

### Claim 65 (depends on 64)

The method of claim 64, wherein about 240 mg of DMF is administered to the subject at one time.

### Claim 66 (depends on 65)

The method of claim 65, wherein the DMF is administered to the subject two times per day (BID) equivalent to a total daily dose of about 480 mg/day.

### Claim 67 (depends on 61)

The method of claim 61, wherein about 20 mg/day of glatiramer acetate is administered to the subject.

### Claim 68 (depends on 61)

The method of claim 61, wherein less than about 20 mg/day of glatiramer acetate is administered to the subject.

### Claim 69 (depends on 61)

The method of claim 61, wherein the compound of Formula I and the glatiramer acetate are administered in amounts and for periods of time sufficient to reduce a relapse rate in the subject.

### Claim 70 (depends on 61)

The method of claim 61, wherein the compound of Formula I and the glatiramer acetate are administered in amounts and for periods of time sufficient to reduce demyelination and/or axonal death in the subject.

### Claim 71 (depends on 52)

The method of claim 52, wherein the MS is relapsing remitting MS.

### Claim 72 (depends on 54)

The method of claim 54, wherein the MS is relapsing remitting MS.

### Claim 73 (depends on 62)

The method of claim 62, wherein the MS is relapsing remitting MS.

### Claim 74 (depends on 64)

The method of claim 64, wherein the MS is relapsing remitting MS.

### Claim 75

A method of treating a subject having multiple sclerosis (MS), the method consisting essentially of:
(a) administering to the subject a therapeutically effective amount of at least one compound of Formula I:
wherein R1 and R2 are independently selected from OH, O−, and (C1-6)alkoxy, or a pharmaceutically acceptable salt thereof, optionally in combination with one or more pharmaceutically acceptable excipients; and
(b) administering to the subject a therapeutically effective amount of interferon-beta, optionally in combination with one or more pharmaceutically acceptable excipients.

### Claim 76

A method of treating a subject having multiple sclerosis (MS), the method comprising:
(a) administering to the subject a therapeutically effective amount of at least one compound of Formula I:
wherein R1 and R2 are independently selected from OH, O−, and (C1-6)alkoxy, or a pharmaceutically acceptable salt thereof; and
(b) administering to the subject a therapeutically effective amount of interferon-beta; wherein the compound of Formula I and the interferon-beta are the only active agents administered to said subject for said treating.
